Huntington's disease brain-derived small RNAs recapitulate associated neuropathology in mice.


Journal

Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041

Informations de publication

Date de publication:
04 2021
Historique:
received: 12 01 2021
accepted: 20 01 2021
revised: 19 01 2021
pubmed: 7 2 2021
medline: 16 11 2021
entrez: 6 2 2021
Statut: ppublish

Résumé

Progressive motor alterations and selective death of striatal medium spiny neurons (MSNs) are key pathological hallmarks of Huntington's disease (HD), a neurodegenerative condition caused by a CAG trinucleotide repeat expansion in the coding region of the huntingtin (HTT) gene. Most research has focused on the pathogenic effects of the resultant protein product(s); however, growing evidence indicates that expanded CAG repeats within mutant HTT mRNA and derived small CAG repeat RNAs (sCAG) participate in HD pathophysiology. The individual contribution of protein versus RNA toxicity to HD pathophysiology remains largely uncharacterized and the role of other classes of small RNAs (sRNA) that are strongly perturbed in HD is uncertain. Here, we demonstrate that sRNA produced in the putamen of HD patients (HD-sRNA-PT) are sufficient to induce HD pathology in vivo. Mice injected with HD-sRNA-PT show motor abnormalities, decreased levels of striatal HD-related proteins, disruption of the indirect pathway, and strong transcriptional abnormalities, paralleling human HD pathology. Importantly, we show that the specific blockage of sCAG mitigates HD-sRNA-PT neurotoxicity only to a limited extent. This observation prompted us to identify other sRNA species enriched in HD putamen with neurotoxic potential. We detected high levels of tRNA fragments (tRFs) in HD putamen, and we validated the neurotoxic potential of an Alanine derived tRF in vitro. These results highlight that HD-sRNA-PT are neurotoxic, and suggest that multiple sRNA species contribute to striatal dysfunction and general transcriptomic changes, favoring therapeutic strategies based on the blockage of sRNA-mediated toxicity.

Identifiants

pubmed: 33547932
doi: 10.1007/s00401-021-02272-9
pii: 10.1007/s00401-021-02272-9
doi:

Substances chimiques

RNA, Small Untranslated 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

565-584

Références

Ament SA, Pearl JR, Cantle JP, Bragg RM, Skene PJ, Coffey SR et al (2018) Transcriptional regulatory networks underlying gene expression changes in Huntington’s disease. Mol Syst Biol 14:e7435. https://doi.org/10.15252/msb.20167435
doi: 10.15252/msb.20167435 pubmed: 29581148 pmcid: 5868199
Anderson P, Ivanov P (2014) tRNA fragments in human health and disease. FEBS Lett 588:4297–4304. https://doi.org/10.1016/j.febslet.2014.09.001
doi: 10.1016/j.febslet.2014.09.001 pubmed: 25220675 pmcid: 4339185
Bañez-Coronel M, Ayhan F, Tarabochia AD, Zu T, Perez BA, Tusi SK et al (2015) RAN translation in Huntington disease. Neuron 88:667–677. https://doi.org/10.1016/j.neuron.2015.10.038
doi: 10.1016/j.neuron.2015.10.038 pubmed: 26590344 pmcid: 4684947
Banez-Coronel M, Porta S, Kagerbauer B, Mateu-Huertas E, Pantano L et al (2012) A pathogenic mechanism in Huntington’s disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet 8:e1002481. https://doi.org/10.1371/journal.pgen.1002481
doi: 10.1371/journal.pgen.1002481 pubmed: 22383888 pmcid: 3285580
Becanovic K, Pouladi MA, Lim RS, Kuhn A, Pavlidis P, Luthi-Carter R et al (2010) Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Hum Mol Genet 19:1438–1452. https://doi.org/10.1093/hmg/ddq018
doi: 10.1093/hmg/ddq018 pubmed: 20089533 pmcid: 2846159
Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A et al (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington’s disease mice. Proc Natl Acad Sci USA 97:6809–6814. https://doi.org/10.1073/pnas.120166397
doi: 10.1073/pnas.120166397 pubmed: 10829080
Blanco S, Dietmann S, Flores JV, Hussain S, Kutter C, Humphreys P et al (2014) Aberrant methylation of tRNAs links cellular stress to neuro-developmental disorders. EMBO J 33:2020–2039. https://doi.org/10.15252/embj.201489282
doi: 10.15252/embj.201489282 pubmed: 25063673 pmcid: 4195770
Brochier C, Gaillard M-C, Diguet E, Caudy N, Dossat C, Segurens B et al (2008) Quantitative gene expression profiling of mouse brain regions reveals differential transcripts conserved in human and affected in disease models. Physiol Genom 33:170–179. https://doi.org/10.1152/physiolgenomics.00125.2007
doi: 10.1152/physiolgenomics.00125.2007
Creus-Muncunill J, Badillos-Rodríguez R, Garcia-Forn M, Masana M, Garcia-Díaz Barriga G, Guisado-Corcoll A et al (2019) Increased translation as a novel pathogenic mechanism in Huntington’s disease. Brain 142:3158–3175. https://doi.org/10.1093/brain/awz230
doi: 10.1093/brain/awz230 pubmed: 31365052
van Dellen A, Welch J, Dixon RM, Cordery P, York D, Styles P et al (2000) N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington’s disease mice. NeuroReport 11:3751–3757
doi: 10.1097/00001756-200011270-00032
Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL et al (2006) Selective deficits in the expression of striatal-enriched mRNAs in Huntington’s disease. J Neurochem 96:743–757. https://doi.org/10.1111/j.1471-4159.2005.03588.x
doi: 10.1111/j.1471-4159.2005.03588.x pubmed: 16405510
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C et al (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15–21. https://doi.org/10.1093/bioinformatics/bts635
doi: 10.1093/bioinformatics/bts635 pubmed: 23104886
Durrenberger PF, Fernando FS, Kashefi SN, Bonnert TP, Seilhean D, Nait-Oumesmar B et al (2015) Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. J Neural Transm 122:1055–1068. https://doi.org/10.1007/s00702-014-1293-0
doi: 10.1007/s00702-014-1293-0 pubmed: 25119539
Ewels P, Magnusson M, Lundin S, Kaller M (2016) MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32:3047–3048. https://doi.org/10.1093/bioinformatics/btw354
doi: 10.1093/bioinformatics/btw354 pubmed: 27312411 pmcid: 5039924
Fourie C, Kim E, Waldvogel H, Wong JM, McGregor A, Faull RLM et al (2014) Differential changes in postsynaptic density proteins in postmortem Huntington’s disease and Parkinson’s disease human brains. J Neurodegener Dis 2014:938530. https://doi.org/10.1155/2014/938530
doi: 10.1155/2014/938530 pubmed: 26317010 pmcid: 4437361
Francelle L, Galvan L, Brouillet E (2014) Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington’s disease. Front Cell Neurosci 8:1–13. https://doi.org/10.3389/fncel.2014.00295
doi: 10.3389/fncel.2014.00295
Garcia-Alcalde F, Okonechnikov K, Carbonell J, Cruz LM, Gotz S, Tarazona S et al (2012) Qualimap: evaluating next-generation sequencing alignment data. Bioinformatics 28:2678–2679. https://doi.org/10.1093/bioinformatics/bts503
doi: 10.1093/bioinformatics/bts503 pubmed: 22914218
García-Amado M, Prensa L (2012) Stereological analysis of neuron, glial and endothelial cell numbers in the human amygdaloid complex. PLoS ONE 7:e38692. https://doi.org/10.1371/journal.pone.0038692
doi: 10.1371/journal.pone.0038692 pubmed: 22719923 pmcid: 3374818
García-Cabezas MÁ, John YJ, Barbas H, Zikopoulos B (2016) Distinction of neurons, glia and endothelial cells in the cerebral cortex: an algorithm based on cytological features. Front Neuroanat 10:107. https://doi.org/10.3389/fnana.2016.00107
doi: 10.3389/fnana.2016.00107 pubmed: 27847469 pmcid: 5088408
Le Gras S, Keime C, Anthony A, Lotz C, De Longprez L, Brouillet E et al (2017) Altered enhancer transcription underlies Huntington’s disease striatal transcriptional signature. Sci Rep 7:42875. https://doi.org/10.1038/srep42875
doi: 10.1038/srep42875 pubmed: 28225006 pmcid: 5320509
Han I, You Y, Kordower JH, Brady ST, Morfini GA (2010) Differential vulnerability of neurons in Huntington’s disease: the role of cell type-specific features. J Neurochem 113:1073–1091. https://doi.org/10.1111/j.1471-4159.2010.06672.x
doi: 10.1111/j.1471-4159.2010.06672.x pubmed: 20236390 pmcid: 2890032
Hanada T, Weitzer S, Mair B, Bernreuther C, Wainger BJ, Ichida J et al (2013) CLP1 links tRNA metabolism to progressive motor-neuron loss. Nature 495:474–480. https://doi.org/10.1038/nature11923
doi: 10.1038/nature11923 pubmed: 23474986 pmcid: 3674495
HDCRG (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell 72:971–983
doi: 10.1016/0092-8674(93)90585-E
Hervas-Corpion I, Guiretti D, Alcaraz-Iborra M, Olivares R, Campos-Caro A, Barco A et al (2018) Early alteration of epigenetic-related transcription in Huntington’s disease mouse models. Sci Rep 8:9925. https://doi.org/10.1038/s41598-018-28185-4
doi: 10.1038/s41598-018-28185-4 pubmed: 29967375 pmcid: 6028428
Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G et al (2006) Regional and cellular gene expression changes in human Huntington’s disease brain. Hum Mol Genet 15:965–977. https://doi.org/10.1093/hmg/ddl013
doi: 10.1093/hmg/ddl013 pubmed: 16467349
Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R et al (1999) A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23:181–192
doi: 10.1016/S0896-6273(00)80764-3
Hoss AG, Kartha VK, Dong X, Latourelle JC, Dumitriu A, Hadzi TC et al (2014) MicroRNAs located in the Hox gene clusters are implicated in Huntington’s disease pathogenesis. PLoS Genet 10:e1004188. https://doi.org/10.1371/journal.pgen.1004188
doi: 10.1371/journal.pgen.1004188 pubmed: 24586208 pmcid: 3937267
Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44–57. https://doi.org/10.1038/nprot.2008.211
doi: 10.1038/nprot.2008.211
Huang DW, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37:1–13. https://doi.org/10.1093/nar/gkn923
doi: 10.1093/nar/gkn923
Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS et al (2015) Orchestrating high-throughput genomic analysis with bioconductor. Nat Methods 12:115–121. https://doi.org/10.1038/nmeth.3252
doi: 10.1038/nmeth.3252 pubmed: 25633503 pmcid: 4509590
Ivanov P, O’Day E, Emara MM, Wagner G, Lieberman J, Anderson P (2014) G-quadruplex structures contribute to the neuroprotective effects of angiogenin-induced tRNA fragments. Proc Natl Acad Sci USA 111:18201–18206. https://doi.org/10.1073/pnas.1407361111
doi: 10.1073/pnas.1407361111 pubmed: 25404306
Jones TR, Kang IH, Wheeler DB, Lindquist RA, Papallo A, Sabatini DM et al (2008) Cell Profiler Analyst: data exploration and analysis software for complex image-based screens. BMC Bioinform 9:482. https://doi.org/10.1186/1471-2105-9-482
doi: 10.1186/1471-2105-9-482
Karaca E, Weitzer S, Pehlivan D, Shiraishi H, Gogakos T, Hanada T et al (2014) Human CLP1 mutations alter tRNA biogenesis, affecting both peripheral and central nervous system function. Cell 157:636–650. https://doi.org/10.1016/j.cell.2014.02.058
doi: 10.1016/j.cell.2014.02.058 pubmed: 24766809 pmcid: 4146440
Krol J, Fiszer A, Mykowska A, Sobczak K, de Mezer M, Krzyzosiak WJ (2007) Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol Cell 25:575–586. https://doi.org/10.1016/j.molcel.2007.01.031
doi: 10.1016/j.molcel.2007.01.031 pubmed: 17317629
Krzyzosiak WJ, Sobczak K, Wojciechowska M, Fiszer A, Mykowska A et al (2012) Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res 40:11–26. https://doi.org/10.1093/nar/gkr729
doi: 10.1093/nar/gkr729 pubmed: 21908410
Labadorf A, Hoss AG, Lagomarsino V, Latourelle JC, Hadzi TC, Bregu J et al (2015) RNA sequence analysis of human huntington disease brain reveals an extensive increase in inflammatory and developmental gene expression. PLoS ONE 10:e0143563. https://doi.org/10.1371/journal.pone.0143563
doi: 10.1371/journal.pone.0143563 pubmed: 4670106 pmcid: 4670106
Labbadia J, Morimoto RI (2013) Huntington’s disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci 38:378–385. https://doi.org/10.1016/j.tibs.2013.05.003
doi: 10.1016/j.tibs.2013.05.003 pubmed: 23768628 pmcid: 3955166
Langfelder P, Cantle JP, Chatzopoulou D, Wang N, Gao F, Al-Ramahi I et al (2016) Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat Neurosci 19:623–633. https://doi.org/10.1038/nn.4256
doi: 10.1038/nn.4256 pubmed: 26900923 pmcid: 5984042
Langfelder P, Gao F, Wang N, Howland D, Kwak S, Vogt TF et al (2018) MicroRNA signatures of endogenous Huntington CAG repeat expansion in mice. PLoS ONE 13:1–20. https://doi.org/10.1371/journal.pone.0190550
doi: 10.1371/journal.pone.0190550
Li L-B, Yu Z, Teng X, Bonini NM (2008) RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 453:1107–1111. https://doi.org/10.1038/nature06909
doi: 10.1038/nature06909 pubmed: 18449188 pmcid: 2574630
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262
doi: 10.1006/meth.2001.1262
Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https://doi.org/10.1186/s13059-014-0550-8
doi: 10.1186/s13059-014-0550-8 pubmed: 25516281 pmcid: 4302049
Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS et al (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington’s disease. Hum Mol Genet 9:1259–1271
doi: 10.1093/hmg/9.9.1259
Marti E (2016) RNA toxicity induced by expanded CAG repeats in Huntington’s disease. Brain Pathol 26:779–786. https://doi.org/10.1111/bpa.12427
doi: 10.1111/bpa.12427 pubmed: 27529325
Martí E, Pantano L, Bañez-Coronel M, Llorens F, Miñones-Moyano E, Porta S et al (2010) A myriad of miRNA variants in control and Huntington’s disease brain regions detected by massively parallel sequencing. Nucleic Acids Res 38:7219–7235. https://doi.org/10.1093/nar/gkq575
doi: 10.1093/nar/gkq575 pubmed: 20591823 pmcid: 2978354
Martin M (2013) Cutadapt removes adapter sequences from high-throughput sequencing reads kenkyuhi hojokin gan rinsho kenkyu jigyo. EMBnet J 17:10–12. https://doi.org/10.14806/ej.17.1.200
doi: 10.14806/ej.17.1.200
Merienne N, Meunier C, Schneider A, Seguin J, Nair SS, Rocher AB et al (2019) Cell-type-specific gene expression profiling in adult mouse brain reveals normal and disease-state signatures. Cell Rep 26:2477-2493.e9. https://doi.org/10.1016/j.celrep.2019.02.003
doi: 10.1016/j.celrep.2019.02.003 pubmed: 30811995
Murmann AE, Gao QQ, Putzbach WE, Patel M, Bartom ET, Law CY et al (2018) Small interfering RNAs based on Huntingtin trinucleotide repeats are highly toxic to cancer cells. EMBO Rep. https://doi.org/10.15252/embr.201745336
doi: 10.15252/embr.201745336 pubmed: 29440125 pmcid: 5836092
Mykowska A, Sobczak K, Wojciechowska M, Kozlowski P, Krzyzosiak WJ (2011) CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res 39:8938–8951. https://doi.org/10.1093/nar/gkr608
doi: 10.1093/nar/gkr608 pubmed: 21795378 pmcid: 3203611
Norden DM, Trojanowski PJ, Villanueva E, Navarro E, Godbout JP (2016) Sequential activation of microglia and astrocyte cytokine expression precedes increased Iba-1 or GFAP immunoreactivity following systemic immune challenge. Glia 64:300–316. https://doi.org/10.1002/glia.22930
doi: 10.1002/glia.22930 pubmed: 26470014
Novati A, Hentrich T, Wassouf Z, Weber JJ, Yu-Taeger L, Deglon N et al (2018) Environment-dependent striatal gene expression in the BACHD rat model for Huntington disease. Sci Rep 8:5803. https://doi.org/10.1038/s41598-018-24243-z
doi: 10.1038/s41598-018-24243-z pubmed: 29643462 pmcid: 5895842
Pantano L, Estivill X, Marti E (2010) SeqBuster, a bioinformatic tool for the processing and analysis of small RNAs datasets, reveals ubiquitous miRNA modifications in human embryonic cells. Nucleic Acids Res 38:e34. https://doi.org/10.1093/nar/gkp1127
doi: 10.1093/nar/gkp1127 pubmed: 20008100
Pantano L, Estivill X, Marti E (2011) A non-biased framework for the annotation and classification of the non-miRNA small RNA transcriptome. Bioinformatics 27:3202–3203. https://doi.org/10.1093/bioinformatics/btr527
doi: 10.1093/bioinformatics/btr527 pubmed: 21976421
Pantano L, Friedlander MR, Escaramis G, Lizano E, Pallares-Albanell J, Ferrer I et al (2016) Specific small-RNA signatures in the amygdala at premotor and motor stages of Parkinson’s disease revealed by deep sequencing analysis. Bioinformatics 32:673–681. https://doi.org/10.1093/bioinformatics/btv632
doi: 10.1093/bioinformatics/btv632 pubmed: 26530722
Patro R, Mount SM, Kingsford C (2014) Sailfish enables alignment-free isoform quantification from RNA-seq reads using lightweight algorithms. Nat Biotechnol 32:462–464. https://doi.org/10.1038/nbt.2862
doi: 10.1038/nbt.2862 pubmed: 24752080 pmcid: 4077321
Pattison LR, Kotter MR, Fraga D, Bonelli RM (2006) Apoptotic cascades as possible targets for inhibiting cell death in Huntington’s disease. J Neurol 253:1137–1142. https://doi.org/10.1007/s00415-006-0198-8
doi: 10.1007/s00415-006-0198-8 pubmed: 16998646
Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WOJ et al (1998) Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 20:198–202. https://doi.org/10.1038/2510
doi: 10.1038/2510 pubmed: 9771716
Richfield EK, Maguire-Zeiss KA, Vonkeman HE, Voorn P (1995) Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington’s disease patients. Ann Neurol 38:852–861. https://doi.org/10.1002/ana.410380605
doi: 10.1002/ana.410380605 pubmed: 8526457
Rikani AA, Choudhry Z, Choudhry AM, Rizvi N, Ikram H, Mobassarah NJ et al (2014) The mechanism of degeneration of striatal neuronal subtypes in Huntington disease. Ann Neurosci 21:112–114. https://doi.org/10.5214/ans.0972.7531.210308
doi: 10.5214/ans.0972.7531.210308 pubmed: 25206077 pmcid: 4158784
Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME et al (2003) Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60:1615–1620
doi: 10.1212/01.WNL.0000065888.88988.6E
Rue L, Banez-Coronel M, Creus-Muncunill J, Giralt A, Alcala-Vida R, Mentxaka G et al (2016) Targeting CAG repeat RNAs reduces Huntington’s disease phenotype independently of huntingtin levels. J Clin Investig 126:4319–4330. https://doi.org/10.1172/JCI83185
doi: 10.1172/JCI83185 pubmed: 27721240
Rué L, López-Soop G, Gelpi E (2013) Brain region-and age-dependent dysregulation of p62 and NBR1 in a mouse model of Huntington’s disease. Neurobiol Dis 52:219–228
doi: 10.1016/j.nbd.2012.12.008
Saavedra A, García-Martínez JM, Xifró X, Giralt A, Torres-Peraza JF, Canals JM et al (2010) PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington’s disease striatum. Cell Death Differ 17:324–335. https://doi.org/10.1038/cdd.2009.127
doi: 10.1038/cdd.2009.127 pubmed: 19745829
Saavedra A, Giralt A, Rué L, Xifró X, Xu J, Ortega Z et al (2011) Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington’s disease: a STEP in the resistance to excitotoxicity. J Neurosci 31:8150–8162
doi: 10.1523/JNEUROSCI.3446-10.2011
Saikia M, Krokowski D, Guan B-J, Ivanov P, Parisien M, Hu G et al (2012) Genome-wide identification and quantitative analysis of cleaved tRNA fragments induced by cellular stress. J Biol Chem 287:42708–42725. https://doi.org/10.1074/jbc.M112.371799
doi: 10.1074/jbc.M112.371799 pubmed: 23086926 pmcid: 3522271
Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K et al (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60:161–172
doi: 10.1093/jnen/60.2.161
Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK et al (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci USA 110:2366–2370. https://doi.org/10.1073/pnas.1221891110
doi: 10.1073/pnas.1221891110 pubmed: 23341618
Schaffer AE, Eggens VRC, Caglayan AO, Reuter MS, Scott E, Coufal NG et al (2014) CLP1 founder mutation links tRNA splicing and maturation to cerebellar development and neurodegeneration. Cell 157:651–663. https://doi.org/10.1016/j.cell.2014.03.049
doi: 10.1016/j.cell.2014.03.049 pubmed: 24766810 pmcid: 4128918
Schmieder R, Lim YW, Edwards R (2012) Identification and removal of ribosomal RNA sequences from metatranscriptomes. Bioinformatics 28:433–435. https://doi.org/10.1093/bioinformatics/btr669
doi: 10.1093/bioinformatics/btr669 pubmed: 22155869
Steibel JP, Poletto R, Coussens PM, Rosa GJM (2009) A powerful and flexible linear mixed model framework for the analysis of relative quantification RT-PCR data. Genomics 94:146–152. https://doi.org/10.1016/j.ygeno.2009.04.008
doi: 10.1016/j.ygeno.2009.04.008 pubmed: 19422910
Swinnen B, Robberecht W, Van Den Bosch L (2020) RNA toxicity in non-coding repeat expansion disorders. EMBO J 39:e101112. https://doi.org/10.15252/embj.2018101112
doi: 10.15252/embj.2018101112 pubmed: 31721251
Thompson DM, Lu C, Green PJ, Parker R (2008) tRNA cleavage is a conserved response to oxidative stress in eukaryotes. RNA 14:2095–2103. https://doi.org/10.1261/rna.1232808
doi: 10.1261/rna.1232808 pubmed: 18719243 pmcid: 2553748
Torres-Peraza JF, Giralt A, Garcia-Martinez JM, Pedrosa E, Canals JM, Alberch J (2008) Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling. Neurobiol Dis 29:409–421. https://doi.org/10.1016/j.nbd.2007.10.003
doi: 10.1016/j.nbd.2007.10.003 pubmed: 18063376
Tsoi H, Lau TC-K, Tsang S-Y, Lau K-F, Chan HYE (2012) CAG expansion induces nucleolar stress in polyglutamine diseases. Proc Natl Acad Sci USA 109:13428–13433. https://doi.org/10.1073/pnas.1204089109
doi: 10.1073/pnas.1204089109 pubmed: 22847428
Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington’s disease. Proc Natl Acad Sci USA 97:8093–8097. https://doi.org/10.1073/pnas.110078997
doi: 10.1073/pnas.110078997 pubmed: 10869421
Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57:369–384
doi: 10.1097/00005072-199805000-00001
Wang L-C, Chen K-Y, Pan H, Wu C-C, Chen P-H, Liao Y-T et al (2011) Muscleblind participates in RNA toxicity of expanded CAG and CUG repeats in Caenorhabditis elegans. Cell Mol Life Sci 68:1255–1267. https://doi.org/10.1007/s00018-010-0522-4
doi: 10.1007/s00018-010-0522-4 pubmed: 20848157
Yang S, Yang H, Huang L, Chen L, Qin Z, Li S et al (2020) Lack of RAN-mediated toxicity in Huntington’s disease knock-in mice. Proc Natl Acad Sci USA 117:4411–4417. https://doi.org/10.1073/pnas.1919197117
doi: 10.1073/pnas.1919197117 pubmed: 32029588
Yu Z-X, Li S-H, Evans J, Pillarisetti A, Li H, Li X-J (2003) Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington’s disease. J Neurosci 23:2193–2202
doi: 10.1523/JNEUROSCI.23-06-02193.2003

Auteurs

Jordi Creus-Muncunill (J)

Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, Barcelona, Catalonia, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain.
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Anna Guisado-Corcoll (A)

Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, Barcelona, Catalonia, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain.

Veronica Venturi (V)

Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology, Dr. Aiguader 88, Barcelona, Catalonia, Spain.

Lorena Pantano (L)

Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Georgia Escaramís (G)

Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Epidemiología y Salud Pública (CIBERESP), Barcelona, Catalonia, Spain.

Marta García de Herreros (M)

Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, Barcelona, Catalonia, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain.

Maria Solaguren-Beascoa (M)

Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, Barcelona, Catalonia, Spain.

Ana Gámez-Valero (A)

Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, Barcelona, Catalonia, Spain.

Cristina Navarrete (C)

Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology, Dr. Aiguader 88, Barcelona, Catalonia, Spain.

Mercè Masana (M)

Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, Barcelona, Catalonia, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain.

Franc Llorens (F)

Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Department of Neurology, National Reference Center for CJD Surveillance, University Medical Center Göttingen, Göttingen, Germany.

Daniela Diaz-Lucena (D)

Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.

Esther Pérez-Navarro (E)

Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, Barcelona, Catalonia, Spain. estherperez@ub.edu.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain. estherperez@ub.edu.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Catalonia, Spain. estherperez@ub.edu.

Eulàlia Martí (E)

Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències, Universitat de Barcelona, Casanova 143, Barcelona, Catalonia, Spain. eulalia.marti@ub.edu.
Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology, Dr. Aiguader 88, Barcelona, Catalonia, Spain. eulalia.marti@ub.edu.
Centro de Investigación Biomédica en Red sobre Epidemiología y Salud Pública (CIBERESP), Barcelona, Catalonia, Spain. eulalia.marti@ub.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH